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Available online 6 August 2015A 48-year-old man with multiple myeloma (immunoglob-
ulin G/kappa) relapsed after receiving bortezomib-based
induction therapy and an autologous stem cell transplant.
Multi-agent salvage chemotherapy was administered and a
haploidentical transplantation (HT) was performed. Two
months later a rapidly enlarging purple mass with prominent
collateral circulation appeared in the right anterior chest
wall, in the site where a previous central venous catheter
was inserted (Figure 1A). A biopsy of the lesion showed tis-
sue infiltration with plasma cells (Figure 1B and C; hema-
toxylin and eosin staining 20 and 40, respectively) that
stained positively for CD38 (Figure 1D; immunohistochemi-
cal staining 20) and exhibited kappa light-chain restriction
(Figure 1E; immunohistochemical staining 40). Shortly
afterward, monoclonal protein in serum became detectable
and blood counts progressively decreased. A diagnosis of
extramedullary progression of multiple myeloma assoft-tissue plasmacytoma was made. No further chemother-
apy was administered; the patient received supportive care
and was discharged home.
Soft-tissue plasmacytomas are the most important form
of extramedullary involvement in multiple myeloma, and
can be found in up to 20% of patients at the time of relapse
[1]. Remarkably, they may be more frequent in patients
relapsing after allogeneic transplantation, possibly because
the graft versus myeloma effect is stronger in the bone mar-
row than in other sites [2]. This risk may be even higher in
patients who received an HT, such as the one presented
here.Conflicts of interest
All contributing authors declare no conflicts of interest.
Figure 1 (A) A rapidly enlarging purple mass with prominent collateral circulation in the right anterior chest wall, where a
previous central venous catheter was inserted. (B and C) A biopsy of the lesion showed tissue infiltration with plasma cells
(hematoxylin and eosin staining 20 and 40, respectively). (D) The cells stained positively for CD38 (immunohistochemical staining
20) and (E) exhibited kappa light-chain restriction (immunohistochemical staining 40).
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